Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc > Odessey Trust
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(55)
•••
Post by Ingiboyon Nov 25, 2024 1:25pm
38 Views
Post# 36329488

Odessey Trust

Odessey TrustThe following information from the Replicel website related to Odyssey Trust:

We are pleased to confirm the following information with respect to the Issuer's upcoming meeting of securityholders: 

Meeting Type: Annual General and Special Meeting 

Meeting Date: December 30, 2024 

Record Date for Notice of Meeting: November 22, 2024 

Record Date for Voting (if applicable): November 22, 2024 

Beneficial Ownership Determination Date: November 22, 2024 

Class of Securities Entitled to Vote: Common 

ISIN: CA76027P4006 

Issuer sending proxy materials directly to NOBOs: No 

Issuer paying for delivery to OBOs: No 

Notice and Access for Beneficial Holders: No 

Notice and Access for Registered Holders: No 

This is a bit confusing to say the least.  What do the above "No's" mean ?

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities